Expertise in
4
conditions

Dr. Anuj Bhargava

Endocrinology
Weight Loss & Wellness Center Of Iowa PLLC
4201 Corporate Dr Ste 100, 
West Des Moines, IA 
Expertise in
4
conditions
Weight Loss & Wellness Center Of Iowa PLLC
4201 Corporate Dr Ste 100, 
West Des Moines, IA 

Overview

Anuj Bhargava is an Endocrinologist in West Des Moines, Iowa. Dr. Bhargava is highly rated in 4 conditions, according to our data. His top areas of expertise are Type 1 Diabetes (T1D), Low Blood Sugar, Type 2 Diabetes (T2D), and Maturity Onset Diabetes of the Young.

His clinical research consists of co-authoring 38 peer reviewed articles and participating in 31 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Endocrinology

Licenses

Internal Medicine in IA

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
HealthPartners
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Wellmark
  • HMO
  • POS
View 12 Less Insurance Carriers -

Locations

Weight Loss & Wellness Center of Iowa PLLC
4201 Corporate Dr Ste 100, West Des Moines, IA 50266
Other Locations
Mercy Clinics Inc.
411 Laurel St Ste 3262, Des Moines, IA 50314

Additional Areas of Focus

Dr. Bhargava has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Non-Alcoholic Fatty Liver Disease
Nonalcoholic Steatohepatitis (NASH)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

31 Clinical Trials

A Randomized, Open-Label, Parallel-Group, Two-Arm, Phase 4 Study to Evaluate the Long-Term Efficacy and Safety of Tirzepatide Compared With Intensified Conventional Care in Adults When Initiating Treatment Early in the Course of Type 2 Diabetes
A Randomized, Open-Label, Parallel-Group, Two-Arm, Phase 4 Study to Evaluate the Long-Term Efficacy and Safety of Tirzepatide Compared With Intensified Conventional Care in Adults When Initiating Treatment Early in the Course of Type 2 Diabetes
Enrollment Status: Active_not_recruiting
Publish Date: December 12, 2025
Intervention Type: Drug
Study Phase: Phase 4
The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (SURPASS-CVOT)
The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (SURPASS-CVOT)
Enrollment Status: Completed
Publish Date: August 24, 2025
Intervention Type: Drug
Study Drugs: Tirzepatide, Dulaglutide
Study Phase: Phase 3
Multi-center, Randomized, Parallel, Adaptive, Controlled Trial in Adult and Pediatric Patients With Type 1 Diabetes Using Hybrid Closed Loop System and Control (CSII, MDI and SAP) at Home
Multi-center, Randomized, Parallel, Adaptive, Controlled Trial in Adult and Pediatric Patients With Type 1 Diabetes Using Hybrid Closed Loop System and Control (CSII, MDI and SAP) at Home
Enrollment Status: Completed
Publish Date: August 19, 2025
Intervention Type: Device
Study Phase: Not Applicable
Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight- Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-1)
Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight- Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-1)
Enrollment Status: Completed
Publish Date: July 24, 2025
Intervention Type: Drug
Study Drug: Tirzepatide
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Parallel-Design, Open-Label Trial to Evaluate the Efficacy and Safety of LY3209590 Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin (QWINT-3)
A Phase 3, Multicenter, Randomized, Parallel-Design, Open-Label Trial to Evaluate the Efficacy and Safety of LY3209590 Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin (QWINT-3)
Enrollment Status: Completed
Publish Date: June 03, 2025
Intervention Type: Drug
Study Drugs: LY3209590, Insulin Degludec
Study Phase: Phase 3
A Phase 3, Parallel-Design, Open-Label, Randomized Control Study to Evaluate the Efficacy and Safety of LY3209590 as a Weekly Basal Insulin Compared to Insulin Degludec in Insulin Naïve Adults With Type 2 Diabetes
A Phase 3, Parallel-Design, Open-Label, Randomized Control Study to Evaluate the Efficacy and Safety of LY3209590 as a Weekly Basal Insulin Compared to Insulin Degludec in Insulin Naïve Adults With Type 2 Diabetes
Enrollment Status: Completed
Publish Date: May 16, 2025
Intervention Type: Drug
Study Phase: Phase 3
INHALE-1: A 26-week Primary Treatment Phase, With 26-week Extension, Open-label, Randomized Clinical Trial Evaluating the Efficacy and Safety of Afrezza® Versus Rapid-acting Insulin Analog Injections, Both in Combination With a Basal Insulin, in Pediatric Subjects With Type 1 or Type 2 Diabetes Mellitus
INHALE-1: A 26-week Primary Treatment Phase, With 26-week Extension, Open-label, Randomized Clinical Trial Evaluating the Efficacy and Safety of Afrezza® Versus Rapid-acting Insulin Analog Injections, Both in Combination With a Basal Insulin, in Pediatric Subjects With Type 1 or Type 2 Diabetes Mellitus
Enrollment Status: Completed
Publish Date: May 06, 2025
Intervention Type: Biological
Study Drugs: Afrezza, Rapid-acting Insulin Analog, Basal Insulin
Study Phase: Phase 3
In-Home Study With MiniMed™ 780G Pump Automated Control in Type 2 - Evaluation of the AHCL System in Adults With Insulin-requiring Type 2 Diabetes
In-Home Study With MiniMed™ 780G Pump Automated Control in Type 2 - Evaluation of the AHCL System in Adults With Insulin-requiring Type 2 Diabetes
Enrollment Status: Completed
Publish Date: February 21, 2025
Intervention Type: Device
Study Phase: Not Applicable
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing the Efficacy and Safety of Tirzepatide Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing the Efficacy and Safety of Tirzepatide Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)
Enrollment Status: Completed
Publish Date: January 24, 2025
Intervention Type: Drug
Study Drug: Tirzepatide
Study Phase: Phase 2
Safety Evaluation of an Advanced Hybrid Closed Loop System Using Lyumjev With the Tandem t:Slim X2 Insulin Pump With Control-IQ Technology in Adults, Adolescents and Children With Type 1 Diabetes
Safety Evaluation of an Advanced Hybrid Closed Loop System Using Lyumjev With the Tandem t:Slim X2 Insulin Pump With Control-IQ Technology in Adults, Adolescents and Children With Type 1 Diabetes
Enrollment Status: Completed
Publish Date: July 26, 2024
Intervention Type: Device
Study Phase: Not Applicable
Efficacy and Safety of Tirzepatide Once Weekly in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-2)
Efficacy and Safety of Tirzepatide Once Weekly in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-2)
Enrollment Status: Completed
Publish Date: April 08, 2024
Intervention Type: Other, Drug
Study Drug: Tirzepatide
Study Phase: Phase 3
A Randomized, Phase 3, Open-label Trial Comparing the Effect of the Addition of Tirzepatide Once Weekly Versus Insulin Lispro (U100) Three Times Daily in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin (SURPASS-6)
A Randomized, Phase 3, Open-label Trial Comparing the Effect of the Addition of Tirzepatide Once Weekly Versus Insulin Lispro (U100) Three Times Daily in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin (SURPASS-6)
Enrollment Status: Completed
Publish Date: November 02, 2023
Intervention Type: Drug
Study Drugs: Tirzepatide, Insulin Lispro, Insulin Glargine
Study Phase: Phase 3
A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo and Dulaglutide in Participants With Type 2 Diabetes
A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo and Dulaglutide in Participants With Type 2 Diabetes
Enrollment Status: Completed
Publish Date: July 03, 2023
Intervention Type: Drug
Study Drugs: LY3437943, Dulaglutide
Study Phase: Phase 2
A Study of LY900014 in Participants With Type 2 Diabetes Using Continuous Glucose Monitoring
A Study of LY900014 in Participants With Type 2 Diabetes Using Continuous Glucose Monitoring
Enrollment Status: Completed
Publish Date: March 03, 2023
Intervention Type: Drug
Study Drugs: LY900014, Insulin Glargine
Study Phase: Phase 3
A Phase 2, Parallel, Comparator-Controlled Trial to Evaluate the Safety and Efficacy of LY3209590 in Insulin-Naïve Patients With Type 2 Diabetes Mellitus
A Phase 2, Parallel, Comparator-Controlled Trial to Evaluate the Safety and Efficacy of LY3209590 in Insulin-Naïve Patients With Type 2 Diabetes Mellitus
Enrollment Status: Completed
Publish Date: November 02, 2022
Intervention Type: Drug
Study Drugs: LY3209590, Insulin Degludec
Study Phase: Phase 2
A Phase 2, Randomized, Parallel, Open-Label Comparator-Controlled Trial to Evaluate the Safety and Efficacy of LY3209590 in Study Participants With Type 1 Diabetes Mellitus Previously Treated With Multiple Daily Injection Therapy
A Phase 2, Randomized, Parallel, Open-Label Comparator-Controlled Trial to Evaluate the Safety and Efficacy of LY3209590 in Study Participants With Type 1 Diabetes Mellitus Previously Treated With Multiple Daily Injection Therapy
Enrollment Status: Completed
Publish Date: October 27, 2022
Intervention Type: Drug
Study Drugs: LY3209590, Insulin Degludec
Study Phase: Phase 2
An Exploratory Study Assessing Time in Target Glucose Range Using a New Titration Scheme of LY900014 and Insulin Degludec in Patients With Type 1 Diabetes
An Exploratory Study Assessing Time in Target Glucose Range Using a New Titration Scheme of LY900014 and Insulin Degludec in Patients With Type 1 Diabetes
Enrollment Status: Completed
Publish Date: June 03, 2022
Intervention Type: Drug
Study Drugs: LY900014, Insulin Degludec
Study Phase: Phase 2
Efficacy and Safety of LY3298176 Once Weekly Versus Insulin Glargine in Patients With Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4)
Efficacy and Safety of LY3298176 Once Weekly Versus Insulin Glargine in Patients With Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4)
Enrollment Status: Completed
Publish Date: February 14, 2022
Intervention Type: Drug
Study Drugs: Tirzepatide, Insulin Glargine
Study Phase: Phase 3
A Prospective, Randomized, Double-Blind Comparison of LY900014 to Humalog With an Open-Label Postprandial LY900014 Treatment Group in Children and Adolescents With Type 1 Diabetes
A Prospective, Randomized, Double-Blind Comparison of LY900014 to Humalog With an Open-Label Postprandial LY900014 Treatment Group in Children and Adolescents With Type 1 Diabetes
Enrollment Status: Completed
Publish Date: January 24, 2022
Intervention Type: Drug
Study Drugs: LY900014, Insulin Lispro
Study Phase: Phase 3
Evaluation of Extended Wear Infusion Set (EWIS) in Patients With Type 1 Diabetes
Evaluation of Extended Wear Infusion Set (EWIS) in Patients With Type 1 Diabetes
Enrollment Status: Completed
Publish Date: October 01, 2021
Intervention Type: Device
Study Phase: Not Applicable
Post Approval Study for Non-Adjunctive Use of Dexcom G5 and G6 CGM System for Diabetes Management
Post Approval Study for Non-Adjunctive Use of Dexcom G5 and G6 CGM System for Diabetes Management
Enrollment Status: Unknown
Publish Date: September 21, 2021
Intervention Type: Device
Continuous Glucose Monitoring (CGM) in Type 2 Diabetes (T2D) Basal Insulin Users: The Mobile Study (MOBILE)
Continuous Glucose Monitoring (CGM) in Type 2 Diabetes (T2D) Basal Insulin Users: The Mobile Study (MOBILE)
Enrollment Status: Completed
Publish Date: April 21, 2021
Intervention Type: Device
Study Phase: Not Applicable
A Phase 2, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of LY3209590 in Study Participants With Type 2 Diabetes Mellitus Previously Treated With Basal Insulin
A Phase 2, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of LY3209590 in Study Participants With Type 2 Diabetes Mellitus Previously Treated With Basal Insulin
Enrollment Status: Completed
Publish Date: March 08, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Prospective, Randomized, Double-Blind Comparison of LY900014 to Humalog in Adults With Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion
A Prospective, Randomized, Double-Blind Comparison of LY900014 to Humalog in Adults With Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion
Enrollment Status: Completed
Publish Date: January 22, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Phase 2 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of TOL-3021 in Patients With New Onset or Established Type 1 Diabetes Mellitus
A Phase 2 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of TOL-3021 in Patients With New Onset or Established Type 1 Diabetes Mellitus
Enrollment Status: Active_not_recruiting
Publish Date: November 09, 2020
Intervention Type: Other, Biological
Study Drug: TOL-3021
Study Phase: Phase 2
A Randomized, Double-Blind, Parallel Arm Study of the Efficacy and Safety of Investigational Dulaglutide Doses When Added to Metformin in Patients With Type 2 Diabetes Mellitus
A Randomized, Double-Blind, Parallel Arm Study of the Efficacy and Safety of Investigational Dulaglutide Doses When Added to Metformin in Patients With Type 2 Diabetes Mellitus
Enrollment Status: Completed
Publish Date: June 12, 2020
Intervention Type: Drug
Study Phase: Phase 3
A Phase 2, Double-Blind, Placebo-Controlled, 18-Week Trial of Investigational Dulaglutide Doses Versus Placebo in Patients With Type 2 Diabetes on Metformin Monotherapy
A Phase 2, Double-Blind, Placebo-Controlled, 18-Week Trial of Investigational Dulaglutide Doses Versus Placebo in Patients With Type 2 Diabetes on Metformin Monotherapy
Enrollment Status: Completed
Publish Date: September 23, 2019
Intervention Type: Drug
Study Phase: Phase 2
Wireless Innovation for Seniors With Diabetes Mellitus (WISDM)
Wireless Innovation for Seniors With Diabetes Mellitus (WISDM)
Enrollment Status: Completed
Publish Date: September 12, 2019
Intervention Type: Device
Study Phase: Not Applicable
A Phase 2 Study of Once-Weekly LY3298176 Compared With Placebo and Dulaglutide in Patients With Type 2 Diabetes Mellitus
A Phase 2 Study of Once-Weekly LY3298176 Compared With Placebo and Dulaglutide in Patients With Type 2 Diabetes Mellitus
Enrollment Status: Completed
Publish Date: August 20, 2019
Intervention Type: Drug
Study Phase: Phase 2
An Objective Assessment of Mealtime Bolus Insulin Behavior and Associated Factors
An Objective Assessment of Mealtime Bolus Insulin Behavior and Associated Factors
Enrollment Status: Completed
Publish Date: August 02, 2019
Intervention Type: Device, Drug
Post Approval Study of the TS (Threshold Suspend) Feature With a Sensor-Augmented Pump System Supplemented With Commercial Patient Data
Post Approval Study of the TS (Threshold Suspend) Feature With a Sensor-Augmented Pump System Supplemented With Commercial Patient Data
Enrollment Status: Completed
Publish Date: March 05, 2019
Intervention Type: Device
Study Phase: Not Applicable
View 30 Less Clinical Trials

38 Total Publications

CGM-derived efficacy and overall safety of once-weekly insulin efsitora alfa (efsitora) relative to day of administration in adults with type 2 diabetes.
CGM-derived efficacy and overall safety of once-weekly insulin efsitora alfa (efsitora) relative to day of administration in adults with type 2 diabetes.
Journal: Diabetes, obesity & metabolism
Published: November 17, 2025
Similar Doctors
Teck Khoo
Expertise in
64
conditions
Dr. Teck Khoo
Endocrinology
Expertise in
64
conditions
Dr. Teck Khoo
Endocrinology

Office

411 Laurel St, 
Des Moines, IA 
 (7.1 miles away)
515-643-5100
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Teck Khoo is an Endocrinologist in Des Moines, Iowa. Dr. Khoo is highly rated in 64 conditions, according to our data. His top areas of expertise are Thyroid Storm, Triple A Syndrome, Graves Disease, and Secondary Adrenal Insufficiency.

Vanitha Singaram
Expertise in
49
conditions
Dr. Vanitha Singaram
Endocrinology
Expertise in
49
conditions
Dr. Vanitha Singaram
Endocrinology

Mercy Clinics Inc.

411 Laurel St Ste 3262, 
Des Moines, IA 
 (6.8 miles away)
515-643-5100
Languages Spoken:
English
See accepted insurances

Vanitha Singaram is an Endocrinologist in Des Moines, Iowa. Dr. Singaram is highly rated in 49 conditions, according to our data. Her top areas of expertise are Thyroid Storm, Graves Disease, Prolactinoma, and Hypothyroidism.

Pierre Theuma
Expertise in
61
conditions
Dr. Pierre Theuma
Endocrinology
Expertise in
61
conditions
Dr. Pierre Theuma
Endocrinology

Office

411 Laurel St, 
Des Moines, IA 
 (7.1 miles away)
515-643-5100
Languages Spoken:
English
See accepted insurances

Pierre Theuma is an Endocrinologist in Des Moines, Iowa. Dr. Theuma is highly rated in 61 conditions, according to our data. His top areas of expertise are Type 2 Diabetes (T2D), Type 1 Diabetes (T1D), Thyroid Storm, and Graves Disease.

Frequently Asked Questions about Dr. Anuj Bhargava

How do I make an appointment with Dr. Anuj Bhargava?

You can book an appointment with Dr. Anuj Bhargava by calling their office at 515-329-6800. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Anuj Bhargava a top-rated expert for Type 1 Diabetes (T1D)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Anuj Bhargava is classified as an Distinguished expert for Type 1 Diabetes (T1D), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Anuj Bhargava specialize in?

While Dr. Anuj Bhargava is a Endocrinology, they have specific expertise in Type 1 Diabetes (T1D), Low Blood Sugar, and Type 2 Diabetes (T2D). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Endocrinology.

Does Dr. Anuj Bhargava participate in research or clinical trials?

Yes. Dr. Anuj Bhargava has published 38 articles and abstracts on conditions like Type 1 Diabetes (T1D). You can view a list of Dr. Anuj Bhargava's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Anuj Bhargava accept my insurance?

Dr. Anuj Bhargava accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 515-329-6800 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Bhargava's expertise for a condition
ConditionClose
      View All 26 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile